logo
Effects of bortezomib on bone disease in multiple myeloma
Erythropoiesis-stimulating agents are effective in myelodysplastic syndromes, but are they safe?
The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo
A phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes
High CD8+ lymphocyte dose in the autograft predicts early absolute lymphocyte count recovery after peripheral hematopoietic stem cell transplantation
High nontransferrin bound iron levels and heart disease in thalassemia major
Familial myeloma and monoclonal gammopathy
sickle cell disease summit
Genetic origins and clinical phenotype of familial and acquired erythrocytosis and thrombocytosis
Hemoglobin Kenya composed of α- and (Aγβ)-fusion-globin chains, associated with hereditary persistence of fetal hemoglobin
Hypochromic microcytic anemia with a variant hemoglobin
Neutrophilic dermatosis of the hands
D-Dimer for the diagnosis of venous thromboembolism in children
Positive impact of maintaining minimal caloric intake above 1.0 × basal energy expenditure on the nutritional status of patients undergoing allogeneic hematopoietic stem cell transplantation
IGF-I treatment of patients with Laron syndrome suppresses serum thrombopoietin levels but does not affect serum erythropoietin